162 related articles for article (PubMed ID: 29806596)
21. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
22. Frequency of Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Expression in Gastric Adenocarcinoma in Rehman Medical Institute Peshawar.
Khattak MT; Hassan M; Nasib B; Qamar MA; Javed S; Ali N
J Pak Med Assoc; 2019 Jun; 69(6):788-793. PubMed ID: 31189283
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma.
Zahir ST; Tafti HF; Rahmani K
Asian Pac J Cancer Prev; 2014; 15(15):6425-8. PubMed ID: 25124637
[TBL] [Abstract][Full Text] [Related]
24. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
Lee EY; Cibull ML; Strodel WE; Haley JV
Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
[TBL] [Abstract][Full Text] [Related]
25. Is Helicobacter Pylori associated with Her2/neu Overexpression in Gastric Cancer Patients who Underwent Curative Resection?
Yoo MW; Han HS; Kim SY; Cho YH; Lee HG; Kim JH; Bang HY; Lee KY; Yoon SY
Hepatogastroenterology; 2014 May; 61(131):858-62. PubMed ID: 26176087
[TBL] [Abstract][Full Text] [Related]
26. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
Shafizadeh N; Grenert JP; Sahai V; Kakar S
Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
[TBL] [Abstract][Full Text] [Related]
28. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
Tanner M; Hollmén M; Junttila TT; Kapanen AI; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
Ann Oncol; 2005 Feb; 16(2):273-8. PubMed ID: 15668283
[TBL] [Abstract][Full Text] [Related]
29. Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages.
Abdel-Aziz A; Ahmed RA; Ibrahiem AT
Ann Diagn Pathol; 2017 Oct; 30():1-7. PubMed ID: 28965621
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.
Oono Y; Kuwata T; Takashima K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
Surg Endosc; 2018 Sep; 32(9):3964-3971. PubMed ID: 29500656
[TBL] [Abstract][Full Text] [Related]
31. Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types.
Peláez Buján Mdel C; Ruibal Morell A; Aza González J
Rev Esp Enferm Dig; 1999 Dec; 91(12):826-37. PubMed ID: 10619912
[TBL] [Abstract][Full Text] [Related]
32. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study.
Ugiagbe EE; Olu-Eddo AN; Obaseki DE
Niger J Clin Pract; 2011; 14(3):332-7. PubMed ID: 22037080
[TBL] [Abstract][Full Text] [Related]
34. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
35. Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer.
Kono K; Takahashi A; Amemiya H; Ichihara F; Sugai H; Iizuka H; Fujii H; Matsumoto Y
Int J Cancer; 2002 Mar; 98(2):216-20. PubMed ID: 11857411
[TBL] [Abstract][Full Text] [Related]
36. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
[TBL] [Abstract][Full Text] [Related]
37. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
38. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J
World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613
[TBL] [Abstract][Full Text] [Related]
39. Her-2/neu assessment for gastric carcinoma: validation of scoring system.
Mrklic I; Bendic A; Kunac N; Bezic J; Forempoher G; Durdov MG; Karaman I; Prusac IK; Pisac VP; Vilovic K; Tomic S
Hepatogastroenterology; 2012; 59(113):300-3. PubMed ID: 22260838
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.
Kim H; Seo S; Kim K; Park YH; An M; Baik H; Choi C; Oh S
World J Surg Oncol; 2019 Jul; 17(1):122. PubMed ID: 31296222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]